Daiichi Sankyo Company and Ranbaxy laboratories have entered into strategic alliance for synergistic initiative in Malaysia where Ranbaxy will market innovative products originally discovered by Daiichi Sankyo. Following Singapore, this is the company’s second marketing synergy in the ASEAN region.
Ranbaxy will market Cravit (levofloxacin), the synthetic antibacterial agent originally discovered by Daiichi Sankyo, in Malaysia from January 1, 2012. The product is currently commercialized by First Pharmaceutical in Malaysia.
Daiichi Sankyo and First Pharmaceutical have agreed to transfer the marketing rights of Cravit (levofloxacin) from First Pharma to Ranbaxy. First Pharma will continue to be Daiichi Sankyo’s marketing partner for other products (except Cravit) it had in-licensed from Daiichi Sankyo.
